(1) Background: As society progresses, increasing numbers of individuals are experiencing hair loss, which can be attributed to factors such as unhealthy diets, insufficient sleep, stress, and hormonal imbalances. Currently available pharmacological treatments for hair loss often cause undesirable side effects, highlighting the urgent need to explore safer and more effective agents to promote hair restoration. This study investigated the role of recombinant human type XVII collagen derived from the α1 chain (rhCOL17A1) in facilitating hair growth and restoration. (2) Methods: We analyzed the impact of rhCOL17A1 on the mRNA expression of several growth factors, as well as Bcl-2 and Bax, at the cellular level. Moreover, the effects of rhCOL17A1 on the expression of key proteins in the Wnt/β-catenin and Sonic Hedgehog (SHH)/GLI signaling pathways were examined by Western blotting (WB). At the organismal level, we established a model in C57BL/6 mice through chronic subcutaneous administration of 5% testosterone propionate. We subsequently assessed the effect of rhCOL17A1 on hair regrowth via histological analysis using hematoxylin and eosin (H&E) staining and immunofluorescence staining. (3) Results: rhCOL17A1 contributes to the resistance of hair follicle dermal papilla cells (HFDPCs) to apoptosis. rhCOL17A1 activates the Wnt/β-catenin and SHH/GLI signaling pathways, and increases the expression of type XVII collagen (COLXVII), thereby creating a favorable environment for hair growth. Furthermore, rhCOL17A1 exerts a significant growth-promoting effect at the animal level. (4) Conclusions: rhCOL17 promotes hair growth by activating the Wnt/β-catenin and SHH/GLI signaling pathways and upregulating COLXVII expression.
Studies have consistently shown that long-wave ultraviolet A (UVA) radiation triggers skin photoaging, which is evident as reduced elasticity, a loss of firmness, and signs of aging. There is an urgent need to investigate photoaging mechanisms to devise protective strategies against UVA. The present study aimed to explore the effects of recombinant type XVII collagen on UVA-induced skin aging and uncover its molecular mechanisms, thereby laying a solid theoretical foundation for precise treatments and prevention. We therefore modeled photoaging damage in HaCaT cells and evaluated collagen-related protein and gene expression levels via western blot analysis and real-time quantitative polymerase chain reaction analysis. Immunofluorescent staining was also used to assess collagen secretion and basement membrane protein expression. Recombinant type XVII collagen significantly boosted type IV and type XVII collagen, laminin alpha 5, and integrin β1 production, thus counteracting UVA-induced collagen decline. The polymerase chain reaction analysis revealed matrix metalloproteinase (MMP) downregulation and tissue inhibitor of metalloproteinase (TIMP) upregulation. Modulating the transforming growth factor (TGF)-β/Smad and epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (MAPK)/activator protein-1 (AP-1) pathways suppressed photoaging. Together, our findings suggest that recombinant type XVII collagen ameliorates UVA-induced damage by reversing MMP and TIMP gene expression, thereby preventing collagen degradation and enhancing basement membrane secretion. These results offer a theoretical basis for potent anti-photoaging products, thus paving the way for innovative solutions against UVA-induced skin aging.
Traumatic non-compressible hemorrhage and subsequent wound management remain critical challenges in military and civilian settings to this day. Cryogels have emerged as promising hemostatic materials for non-compressible hemorrhage due to their blood-triggered shape recovery. In this study, a biodegradable and mechanically resilient cryogel (CF/PD) was produced via cryopolymerization, employing methacrylated recombinant collagen as a macromolecular crosslinker alongside poly (ethylene glycol) diacrylate (PEGDA) and dopamine methacrylate (DMA). With its interpenetrating macro-porous structure and high hydrophilicity, the CF/PD rapidly absorbs blood and returns to its original shape within 1.5 s. In a rat liver defect model, CF/PD outperformed commercially available gelatin sponges, reducing hemostasis time by 74.4% and blood loss by 76.5%. Moreover, CF/PD cryogels facilitate in situ tissue regeneration by virtue of the bioactivity and degradability of recombinant collagen. This work establishes a bioactive recombinant collagen-driven cryogel platform, offering a transformative solution for managing non-compressible hemorrhage while enabling tissue regeneration.